within Pharmacolibrary.Drugs.ATC.C;

model C04AX32
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.4166666666666667,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fasudil is a selective Rho-kinase inhibitor primarily used in the treatment of cerebral vasospasm following subarachnoid hemorrhage and has been investigated for use in pulmonary hypertension and other vascular conditions. It is approved in Japan but not widely approved elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult healthy male volunteers after intravenous administration.</p><h4>References</h4><ol><li>Nilesh Gupta, Fahad I Al-Saikhan, Brijeshkumar Patel, Jahidur Rashid, Fakhrul Ahsan,Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs.,International journal of pharmaceutics,2015<a href='https://pubmed.ncbi.nlm.nih.gov/25888802/'>https://pubmed.ncbi.nlm.nih.gov/25888802/</a></li><li>Saeko Takase, Jingzhu Liao, Yue Liu, Rinako Tanaka, Yasuhiro Miyagawa, Masahito Sawahata, Akira Sobue, Hiroyuki Mizoguchi, Taku Nagai, Kozo Kaibuchi, Norio Ozaki, Kiyofumi Yamada,Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia.,European journal of pharmacology,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35987254/'>https://pubmed.ncbi.nlm.nih.gov/35987254/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AX32;
